Hungarian Translations

Neurology® 2012; Vol. 78

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society, Silberstein et al. 78(17):1337-1345

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease, Richard et al. 78(16):1229-1236

Blood–brain barrier: Recent developments and clinical correlations, Benarroch 78(16):1268-1276

Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors, Pariente et al. 78(13):957-963

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Patwa at al. 78(13):1009-1015

Intravenous thrombolysis in young stroke patients: Results from the SITS-ISTR, Toni et al. 78(12):880-887

GABAB receptors: Structure, functions, and clinical implications, Benarroch 78(8):578-584

“On” state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication, Espay et al. 78(7):454-457

Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients, Knottnerus et al. 78(7):493-498

Multimodal endovascular reperfusion therapies: Adjunctive antithrombotic agents in acute stroke, Lazzaro and Zaidat 78(7):501-506

Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance, Blair et al. 78(7):507-508

Amyloid pathology in persons with 'normal' cognition, Buchman and Bennett 78(4):228-229

The good, bad, and ugly?: How blood nutrient concentrations may reflect cognitive performance, Tangney and Scarmeas 78(4):230-231

APOE modifies the association between Aβ load and cognition in cognitively normal older adults, Kantarci et al. 78(4):232-240

Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging, Bowman et al. 78(4):241-249

Prestroke/poststroke fMRI in aphasia: Perilesional hemodynamic activation and language recovery, Lidzba et al. 78(4):289-291

 

Neurology® 2011; Vol. 77

Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Scott et al. 77(24):2128-2134

POLG-related disorders: Defects of the nuclear and mitochondrial genome interaction, Milone et al. 77(20):1847-1852

Blood markers in TIA: Array of hope?, Cucchiara and Nyquist 77(19):1716-1717

Transient ischemic attacks characterized by RNA profiles in blood, Zhan et al. 77(19):1718-1724

Parkinson disease: The enteric nervous system spills its guts, Derkinderen et al. 77(19):1761-1767

MR brain iron mapping in MS: A potential neurodegenerative marker or just another technique?, Rovira and Montalban 77(18):1660-1661

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis, Sormani et al. 77(18):1684-1690

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis, Stein et al. 77(17):1611-1618

Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS, Ito and Suzuki 77(17):1636-1643

Is levodopa toxic?: Insights from a brain bank, LeWitt et al. 77(15):1414

Does levodopa accelerate the pathologic process in Parkinson disease brain?, Parkkinen et al. 77(15):1420-1426

Quantitative EEG as a predictive biomarker for Parkinson disease dementia, Klassen et al. 77(2):118-124

 

Neurology® 2011; Vol. 76

Will my baby walk?: The predictive value of cranial imaging, Guillet and Dees 76(24):2048-2049

Predicting motor outcome and death in term hypoxic-ischemic encephalopathy, Martinez-Biarge et al. 76(24):2055-2061

A multicenter assessment of cervical cord atrophy among MS clinical phenotypes, Rocca et al. 76(24):2096-2102

Etiologic investigation of ischemic stroke in young adults, Larrue et al. 76(23):1983-1988

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, O'Connor et al. 76(22):1858-1865

Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links, Sokol et al. 76(15):1344-1352

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS, Kowarik et al. 76(14):1214-1221

Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications, Popescu et al. 76(14):1229-1237

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy, Gong et al. 76(13):1126-1134

Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis?, Tumani and Cadavid 76(12):1034-1035

A prospective study on the role of CXCL13 in Lyme neuroborreliosis, Schmidt et al. 76(12):1051-1058

Classification of primary progressive aphasia and its variants, Gorno-Tmpini et al. 76(11):1006-1014

Genotype —phenotype associations in SCN1A-related epilepsies, Zuberi et al. 76(7):594-600

Heat shock proteins: Multiple neuroprotective functions and implications for neurologic disease, Benarroch 76(7):660-667

Sun exposure and vitamin D are independent risk factors for CNS demyelination, Lucas et al. 76(6):540-548

Stress hormones predict cerebrovascular re-events after transient ischemic attacks, Katan et al. 76(6):563-566

Bevacizumab antiangiogenic therapy for glioblastoma, Junck 76(5):414-415

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab, Pope 76/5/432

White matter synapses: Form, function, and dysfunction, Alix and Domingues 76(4):397-404

MHC transmission: Insights into gender bias in MS susceptibility, Chao et al. 76(3):242-246

Three-month stroke outcome: The European Registers of Stroke (EROS) Investigators, Heuschmann et al. 76(2):159-165